Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells

PURPOSE: Inhibition of vascular endothelial growth factor (VEGF) is a promising strategy to treat retinal complications of diabetes. In contrast to VEGF-A binding ranibizumab, aflibercept also binds to other members of the VEGF family including VEGF-B, but potential effects of this factor on permeab...

Descripción completa

Detalles Bibliográficos
Autores principales: Deissler, Heidrun L., Lang, Gerhard K., Lang, Gabriele E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Basic Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445774/
https://www.ncbi.nlm.nih.gov/pubmed/25663437
http://dx.doi.org/10.1007/s00417-015-2944-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445774/
https://www.ncbi.nlm.nih.gov/pubmed/25663437
http://dx.doi.org/10.1007/s00417-015-2944-z

Ejemplares similares